Buch, Englisch, Band 26, 358 Seiten, Format (B × H): 156 mm x 234 mm, Gewicht: 1560 g
Buch, Englisch, Band 26, 358 Seiten, Format (B × H): 156 mm x 234 mm, Gewicht: 1560 g
Reihe: Cancer Treatment and Research
ISBN: 978-0-89838-702-5
Verlag: Springer Us
Where do you begin to look for a recent, authoritative article on the diagnosis or management of a particular malignancy? The few general on cology textbooks are generally out of date. Single papers in specialized jour nals are informative but seldom comprehensive; these are more often pre liminary reports on a very limited number of patients. Certain general jour nals frequently publish good indepth reviews of cancer topics, and published symposium lectures are often the best overviews available. Unfortunately, these reviews and supplements appear sporadically, and the reader can nev er be sure when a topic of special interest will be covered. Cancer Treatment and Research is a series of authoritative volumes which aim to meet this need. It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, easily available on a single library shelf or by a single personal subscription. We have approached the problem in the following fashion. First, by di viding the oncology literature into specific subdivisions such as lung cancer, genitourinary cancer, pediatric oncology, etc. Second,. by asking eminent authorities in each of these areas to edit a volume on the specific topic on an annual or biannual basis. Each topic and tumor type is covered in a volume appearing frequently and predictably, discussing current diagnosis, staging, markers, all forms of treatment modalities, basic biology, and more.
Zielgruppe
Research
Autoren/Hrsg.
Fachgebiete
Weitere Infos & Material
1. Retroviruses and Onc Genes in Human Leukemias and Lymphomas.- 1.1 Introduction.- 1.2 Onc Genes in Leukemogenesis.- 1.3 Retroviruses in Human Leukemia-Lymphoma.- 2. Study of Differentiation and Proliferation of Leukemic Cells Using Myeloid Leukemia Cell Lines.- 2.1 Introduction: Establishment of Human Myeloid Leukemia Cell Lines.- 2.2 Human Erythroleukemia Cell Lines.- 2.3 Study of Granulocyte Differentiation Using Myeloid Leukemic Cell Lines.- 2.4 Induction of Macrophage-Like Differentiation of Human Acute Myelogenous Cells.- 2.5 Genetic Analysis of Myeloid Differentiation.- 2.6 Hormonal Modulation of Leukemic Cell Growth.- 2.7 An In Vitro Model for Chemotherapy of Acute Myelogenous Leukemia.- 2.8 Conclusion.- Acknowledgements.- References.- 3. Biological Markers in Lymphoproliferative Disorders.- 3.1 Introduction.- 3.2 Immunological Markers.- 3.3 Chronic B-Cell Malignancies.- 3.4 Chronic T-Cell Malignancies.- 3.5 Cytochemistry of Acid Hydrolases.- 3.6 Chromosomes.- 3.7 Conclusions.- Acknowledgements.- References.- 4. Surface Marker Analysis of Acute Myeloblasts Leukemia.- 4.1 Introduction.- 4.2 Differentiation of Normal Myeloid Cells.- 4.3 Detection of Myeloid-Lineage Antigens by Heteroantisera.- 4.4 Production of Monoclonal Antibodies to Myeloid Cell Surface Antigens.- 4.5 Monoclonal Antibodies Reactive with Human AML Cells.- 4.6 Expression of Myeloid Differentiation Antigens on AML Cells.- 4.7 Future Directions.- References.- 5. Classification of 358 Cases of Acute Myeloid Leukemia by FAB Criteria: Analysis of Clinical and Morphologic Features.- 5.1 Introduction.- 5.2 Clinical and Morphologic Characteristics of the FAB Classes.- 5.3 Comparison of FAB Classes of AML.- 5.4 Discussion.- References.- 6. Chemosensitivity of In Vitro Colony Forming Units as a Predictorof Response to Antileukemic Drugs.- 6.1 Introduction.- 6.2 Colony Assays.- 6.3 Quantitation of Sensitivity to Antileukemic Drugs.- 6.4 Correlations Between In Vitro Chemosensitivities of L-CFU and Clinical Response of the Patient.- 6.5 Summary.- References.- 7. Post-Remission Therapy for Acute Myelogenous Leukemia.- 7.1 Introduction.- 7.2 Role of Induction Therapy on Remission Duration.- 7.3 Role of Consolidation Therapy on Remission Duration.- 7.4 Role of Maintenance Chemotherapy in Prolonging Remissions.- 7.5 The Role of Immunotherapy in Maintenance.- 7.6 Prognostic Variables Predicting for Prolonged Remission Duration.- 7.7 Central Nervous System Leukemia.- 7.8 Bone Marrow Transplantation.- 7.9 Summary and Conclusions.- Acknowledgement.- References.- 8. The Role of Marrow Transplantation in the Treatment of Leukemia.- 8.1 Introduction.- 8.2 Donor Selection.- 8.3 Preparative Regimens.- 8.4 Techniques of Marrow Transplantation.- 8.5 Clinical Results in Acute Nonlymphoblastic Leukemia (ANL).- 8.6 Clinical Results in Acute Lymphoblastic Leukemia (ALL).- 8.7 Clinical Results in Chronic Granulocytic Leukemia (CGL).- 8.8 Leukemic Recurrence After Transplantation.- 8.9 Graft-Versus-Host Disease (GVHD).- 8.10 Infectious Complications, Including Interstitial Pneumonia.- 8.11 Other Organ Toxicities.- 8.12 Summary.- Acknowledgements.- References.- 9 Hyperleukemias in Adult Leukemia.- 9.1 Introduction.- 9.2 Acute Myelocytic Leukemia.- 9.3 Chronic Myelocytic Leukemia.- 9.4 Acute Lymphocytic Leukemia.- 10 New Developments in the Etiology, Diagnosis, Treatment and Prevention of Infectious Complications in Patients with Leukemia.- 10.1 Introduction.- 10.2 Changing Patterns of Infections.- 10.3 New Developments in Evaluation and Diagnosis.- 10.4 Developments in Antimicrobial Therapy.-10.5 New or Evolving Syndromes in Management of Infections in the Adult Leukemic.- 10.6 Recent Developments in Adjuvant Therapy.- 10.7 Current Concepts in Infection Prevention in Acute Leukemia.
